Hepta Unveils AI Liquid Biopsy for Chronic Disease
November 12, 2025, 3:48 am
Location: United States, California, Menlo Park
Employees: 11-50
Founded date: 2006
Location: United States, California, Foster City
Employees: 1-10
Founded date: 2014
Hepta secures $6.7M. It pioneers AI-driven liquid biopsy for chronic diseases, starting with MASH. Its transformer AI platform analyzes cell-free DNA epigenomes. This delivers unparalleled precision in diagnosis. The non-invasive blood test provides tissue-level insights, overcoming current diagnostic hurdles like invasive biopsies or unreliable standard tests. It dramatically reduces false positives for metabolic liver disease. This breakthrough technology, backed by ex-Illumina and Google experts, promises to redefine early detection and management for millions affected by chronic conditions, opening doors for timely therapeutic interventions. Hepta aims to scale its platform, validate further, and engage pharmaceutical partners. This marks a pivotal shift in chronic disease diagnostics.
Hepta emerges from stealth. The biotechnology firm announces significant seed funding. It secured $6.7 million. Felicis Ventures and Illumina Ventures co-led the round. SeaX Ventures, Alumni Ventures, and AME Cloud Ventures also participated. This capital infusion will advance Hepta's groundbreaking AI diagnostics. The focus is on chronic diseases. A new era of non-invasive detection begins.
Chronic diseases pose immense health challenges. They represent a diagnostic crisis. Current methods often fall short. Many are invasive. Others lack accuracy. This leaves millions undiagnosed. Early intervention suffers. Hepta aims to bridge this gap. It introduces a novel approach.
The company targets Metabolic Dysfunction-Associated Steatohepatitis (MASH). MASH, formerly NASH, is a severe liver condition. Over 20 million Americans suffer from it. Yet, diagnosis remains alarmingly low. Less than one percent receive a proper diagnosis. This stems from limited testing capacity. Existing tools are inadequate.
Liver biopsies are invasive. They carry risks. They are not scalable for mass screening. Specialized imaging offers some insight. But access is scarce. Less than 10% of primary care settings possess devices like FibroScan. Standard blood tests exist. FIB-4 is one example. However, these tests produce high error rates. Over half of patients get false positives. This leads to unnecessary anxiety or missed diagnoses. Clinicians need better tools. Patients deserve clarity.
Hepta offers a breakthrough. Its platform uses a simple blood draw. It delivers tissue-level insights. This is specialist-grade precision. It becomes available in routine care. This changes the diagnostic landscape for MASH. It removes barriers.
The core technology is innovative. Hepta employs transformer-based AI. This AI reads the cell-free DNA (cfDNA) epigenome. CfDNA circulates freely in the bloodstream. It carries epigenetic signals. These signals indicate organ health. Hepta’s AI deciphers them.
Oncology has seen liquid biopsy success. These assays look for distinct mutations. Chronic diseases present a different challenge. Their signals are far fainter. They involve subtle epigenetic shifts. Hepta's platform is specifically optimized for these faint signals. It is a liquid-biopsy-native transformer model.
This advanced architecture powers large language models. Hepta scales it for molecular data. It analyzes up to one billion unique molecules per sample. This is an immense data processing capability. Traditional methods analyze smaller segments. They miss crucial patterns. Hepta's system processes all molecular interactions simultaneously. This uncovers previously invisible patterns.
Clinical data supports Hepta's claims. Its AI-powered platform identifies MASH patients. It focuses on those with significant fibrosis. The diagnostic AUC is 0.86. This demonstrates high accuracy. Crucially, it cuts false positives threefold. This is compared to standard blood tests. Such performance enables immediate clinical action. New MASH therapies are entering the market. Accurate diagnosis becomes paramount.
The MASH Atlas dataset validates the technology. Hepta developed it with Duke University. This dataset shows strong concordance. It links cfDNA methylation to liver tissue biology. This confirms the platform's ability. It acts as a true liquid biopsy of the liver. It provides organ-level biological profiles.
Hepta's team brings unparalleled expertise. Founders previously led efforts at Illumina, Grail, and Google. They scaled next-generation sequencing. They built early liquid biopsy platforms for oncology. Now, they apply this knowledge to chronic disease. Their vision extends beyond MASH.
The platform holds vast potential. It offers non-invasive diagnostics. It can guide precision therapies. It enables disease progression monitoring. This could reshape chronic disease management entirely. Starting with MASH, Hepta sets a new standard.
The company plans for the future. It will expand its datasets. It will advance regulatory pathways. Commercialization efforts are underway. New clinical findings will be presented. These will feature at upcoming medical conferences. Hepta also engages pharmaceutical partners. They seek to integrate diagnostic intelligence. This supports treatment programs.
Hepta addresses a critical unmet need. Accurate liver diagnostics will expand access to care. It moves beyond specialized tertiary centers. It empowers primary care providers. It transforms a global epidemic. Millions will benefit from earlier, more precise diagnosis. Hepta is leading this revolution. It promises a brighter future for chronic disease detection.
Hepta emerges from stealth. The biotechnology firm announces significant seed funding. It secured $6.7 million. Felicis Ventures and Illumina Ventures co-led the round. SeaX Ventures, Alumni Ventures, and AME Cloud Ventures also participated. This capital infusion will advance Hepta's groundbreaking AI diagnostics. The focus is on chronic diseases. A new era of non-invasive detection begins.
Chronic diseases pose immense health challenges. They represent a diagnostic crisis. Current methods often fall short. Many are invasive. Others lack accuracy. This leaves millions undiagnosed. Early intervention suffers. Hepta aims to bridge this gap. It introduces a novel approach.
The company targets Metabolic Dysfunction-Associated Steatohepatitis (MASH). MASH, formerly NASH, is a severe liver condition. Over 20 million Americans suffer from it. Yet, diagnosis remains alarmingly low. Less than one percent receive a proper diagnosis. This stems from limited testing capacity. Existing tools are inadequate.
Liver biopsies are invasive. They carry risks. They are not scalable for mass screening. Specialized imaging offers some insight. But access is scarce. Less than 10% of primary care settings possess devices like FibroScan. Standard blood tests exist. FIB-4 is one example. However, these tests produce high error rates. Over half of patients get false positives. This leads to unnecessary anxiety or missed diagnoses. Clinicians need better tools. Patients deserve clarity.
Hepta offers a breakthrough. Its platform uses a simple blood draw. It delivers tissue-level insights. This is specialist-grade precision. It becomes available in routine care. This changes the diagnostic landscape for MASH. It removes barriers.
The core technology is innovative. Hepta employs transformer-based AI. This AI reads the cell-free DNA (cfDNA) epigenome. CfDNA circulates freely in the bloodstream. It carries epigenetic signals. These signals indicate organ health. Hepta’s AI deciphers them.
Oncology has seen liquid biopsy success. These assays look for distinct mutations. Chronic diseases present a different challenge. Their signals are far fainter. They involve subtle epigenetic shifts. Hepta's platform is specifically optimized for these faint signals. It is a liquid-biopsy-native transformer model.
This advanced architecture powers large language models. Hepta scales it for molecular data. It analyzes up to one billion unique molecules per sample. This is an immense data processing capability. Traditional methods analyze smaller segments. They miss crucial patterns. Hepta's system processes all molecular interactions simultaneously. This uncovers previously invisible patterns.
Clinical data supports Hepta's claims. Its AI-powered platform identifies MASH patients. It focuses on those with significant fibrosis. The diagnostic AUC is 0.86. This demonstrates high accuracy. Crucially, it cuts false positives threefold. This is compared to standard blood tests. Such performance enables immediate clinical action. New MASH therapies are entering the market. Accurate diagnosis becomes paramount.
The MASH Atlas dataset validates the technology. Hepta developed it with Duke University. This dataset shows strong concordance. It links cfDNA methylation to liver tissue biology. This confirms the platform's ability. It acts as a true liquid biopsy of the liver. It provides organ-level biological profiles.
Hepta's team brings unparalleled expertise. Founders previously led efforts at Illumina, Grail, and Google. They scaled next-generation sequencing. They built early liquid biopsy platforms for oncology. Now, they apply this knowledge to chronic disease. Their vision extends beyond MASH.
The platform holds vast potential. It offers non-invasive diagnostics. It can guide precision therapies. It enables disease progression monitoring. This could reshape chronic disease management entirely. Starting with MASH, Hepta sets a new standard.
The company plans for the future. It will expand its datasets. It will advance regulatory pathways. Commercialization efforts are underway. New clinical findings will be presented. These will feature at upcoming medical conferences. Hepta also engages pharmaceutical partners. They seek to integrate diagnostic intelligence. This supports treatment programs.
Hepta addresses a critical unmet need. Accurate liver diagnostics will expand access to care. It moves beyond specialized tertiary centers. It empowers primary care providers. It transforms a global epidemic. Millions will benefit from earlier, more precise diagnosis. Hepta is leading this revolution. It promises a brighter future for chronic disease detection.